This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hogervorst, F. B. L. Articles by Pals, G. Search for Related Content PubMed PubMed Citation Articles by Hogervorst, F. B. L. Articles by Pals, G.

Large Genomic Deletions and Duplications in the BRCA1 Gene Identified by a Novel Quantitative Method

Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam [F. B. L. H., P. M. N., R. P., R. R., T. v. W., I. K., C. D., S. V., L. J. v. V.]; Family Cancer Clinic, Department of Clinical Genetics and Human Genetics, VU Medical Center, 1081 BT Amsterdam [J. J. P. G., M. G., R. v. S., F. H. M., C. D., G. P.]; MRC-Holland, Amsterdam [C. J. M., T. v. W., J. P. S.]; and Department of Clinical Genetics, Amsterdam Medical Center, Amsterdam [I. K., S. V.], the Netherlands

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
We applied a novel method to detect single or multiple exon deletions and amplifications in the BRCA1 gene. The test, called multiplex ligation-dependent probe amplification (MLPA), uses probes designed to hybridize adjacently to the target sequence. After ligation, the joined probes are amplified and quantified. Our two diagnostic laboratories have tested in the recent years 805 families by conventional PCR-based techniques, and found 116 BRCA1 and 28 BRCA2 mutation-positive families. Using MLPA, we have tested the remaining 661 noninformative breast cancer families and identified five distinct BRCA1 germ-line mutations in five families: a deletion of exon 8, a deletion of exons 20–22, a duplication of exon 13 and exons 21–23, respectively, and a triplication, encompassing exons 17–19. Genomic deletions of BRCA1 constitute a substantial fraction of mutations in Dutch breast cancer families. If MLPA had been included in our initial BRCA1 testing, 33 families with a deletion or duplication would have been identified, representing 27% of the total 121 BRCA1 mutation-positive families. The MLPA test for BRCA1 ensures a sensitive and comprehensive high-throughput screening test for genomic rearrangement and can easily be implemented in the molecular analysis of BRCA1.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
Germ-line mutations in the BRCA1 gene cause a hereditary predisposition to breast and ovarian cancer. Methods used to screen for mutations focus on genomic DNA and are usually PCR-based, enabling the detection of sequence alterations such as point mutations, and small deletions and insertions. By this approach, thousands of BRCA1 families have been identified worldwide (the Breast Cancer Information Core on the Internet).² An increasing number of large genomic alterations have been described recently as laboratories put more effort into the detection of such alterations. At present, >18 different large genomic rearrangements have been characterized; they include both deletions and duplications of one or more exons in BRCA1 (1, 2, 3, 4, 5, 6) . Although for some recurrent mutations a simple PCR test has been developed (4 , 5) , the gold standard to search for aberrant copy numbers of one or more exons is Southern blotting. However, this technique is time consuming and laborious and, therefore, screening is usually restricted to selected families (1, 2, 3, 4 , 7 , 8) . Ideally, all of the individuals eligible for BRCA1 mutation screening should be screened for the presence of large genomic deletions and duplications. Therefore, we applied a new method, called MLPA,³ which enables us to determine the relative copy number of all of the BRCA1 exons simultaneously with high sensitivity in a high-throughput format (9) . We have shown recently that this method is very successful in the identification of large genomic deletions in the hMLH1 and hMSH2 genes in hereditary nonpolyposis colorectal carcinoma families (10) . The principle of this technique is shown in Fig. 1 . In brief, only adjacently hybridized and subsequently ligated probes can be amplified by PCR. Because up to 40–50 target sequences can be analyzed simultaneously, the complete BRCA1 gene can be screened in one single reaction. Fragment analysis is carried out on an automated, preferably capillary, sequencer identifying each of the fragments based on the specific PCR fragment length. The measured peak area is used to calculate the relative quantity of each probe. In this report we show the results of the MLPA-BRCA1 analyses of >660 breast and/or ovarian cancer families, reveal alterations not reported before, and conclude that the method is reliable and very suitable to be included in the routine molecular analysis of predisposed families.

View larger version (25K): [in this window] [in a new window]   Fig. 1. Principle of MLPA. For each specific target, a set of two probes was designed that hybridize immediately adjacent to each other on the same target strand. Both probes consist of a short (22–43 nt) target-specific sequence and a universal forward or reverse PCR primer-binding site. In addition, one of the probes contains a so-called stuffer sequence. For each probe, the stuffer part has a specific length (19–364 bp) and sequence. The long probes are M13-derived. The short probes are synthetic. After an overnight hybridization to the target DNA, the two parts of each hybridized probe are joined by a ligation reaction. Next, a PCR is carried out with a single fluorescent-labeled primer pair, which ensures that the relative yield of the PCR products is proportional to the amount of target. The fragment analysis is preferably carried out on an automated capillary sequencer. The multiple fragments can be distinguished based on different length. The peak area value of each product is used to calculate the relative quantity.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

MLPA Reaction and Fragment Analysis.
The BRCA1-MLPA test was developed and manufactured by MRC-Holland in close collaboration with one of the authors (G. P.). The preparation and sequences of the probes has been described elsewhere (9) .⁴ The BRCA1-MLPA test itself is commercially available at MRC-Holland. In short, 50–500 ng target DNA/5 µl of 10 mM Tris (pH 8)-0.1 mM EDTA was denatured for 5 min at 98°C after which 3 µl of the probe mix was added. The mixture was heated at 95°C for 1 min and incubated at 60°C overnight (16 h). Ligation was performed with the temperature-stable Ligase-65 enzyme (MRC-Holland) for 15 min at 54°C. Next, the ligase was inactivated by incubation for 5 min at 98°C. Ten µl of this ligation mix was premixed with 30 µl of PCR buffer and put in a PCR machine at 60°C. Subsequently, a 10-µl mix was added containing deoxynucleoside triphosphate, Taq polymerase, and one unlabeled and one carboxyfluorescein-labeled PCR primer, which are complementary to the universal primer sequences. PCR was carried out for 33 cycles (30 s at 95°C, 30 s at 60°C, and 60 s at 72°C). The fragments were analyzed on an ABI model 310 or 3700 capillary sequencer (Applied Biosystems) using Genescan-ROX 500 size standards (Applied Biosystems). Fragment analysis was performed using Genescan and Genotyper software.

Quantitative and Statistical Analysis.
To automate the interpretation of the fragment analysis, the relative quantity of the amplified probes in each sample was determined using an Excel template. For this purpose, the relative peak areas for each probe were calculated as fractions of the total sum of peak areas in a certain sample. Subsequently, the fraction of each peak was divided by the average peak fractions of the corresponding probe in control samples. Finally, the values were normalized using the values obtained for the autosomal control probes, which served as a reference for the copy number of 2.0. Between 2 and 8% of the samples showed a variation >20% in the control genes. They were removed from the quantification calculations and retested. The great variation was because of either the high quantity of the input DNA or the DNA extraction method, in particular, because of the presence of residues of agents (like phenol). In general, reduction of the amount of input DNA yielded less variation.

Confirmation of Rearrangements by PCR.
Primers for the exon 13 duplication were described by Puget et al. (5) . For the newly discovered deletion of exons 8 and 20–22, primers were designed located in the flanking introns. The primer combination for the exon 8 deletion is: forward primer (nt 27164; GenBank accession no. L78833) 5'-GTTGGGCTTTTAAATACTCGTTCC-3' and reverse primer (nt 29530) 5'-CCTATTGCTACTCTCCATCTTTCC-3'. The deletion of exons 20–22 could be detected using forward primer (nt 67911) 5'AGATAGGCCAATGTTGGTCG- 3' and reverse primer (nt 81183) 5'-ACTGTGCTACTCAAGCACCA-3'. The recombination site was sequenced using forward primer (nt 68664) 5'-GCTGGGAATGGTGGCATGTG-3'. The primer combination for the elucidation of the exons 21–23 duplication is forward primer (nt 81291) 5'-GGGTGGGAGTAAGATATGAAT-3' and reverse primer (nt 75461) 5'-TGGAGCCAAATGCTGACATGA-3'. The primer combination used for the triplication of exons 17–19 is: forward (nt 66183) 5'-AAGAAACAGTCCTTTCTTTGGG)-3' and reverse (nt 58949) 5'-GATGAAAAATCCTAGGAAGG-3'.

Sequence Analysis.
Purified PCR products, encompassing the recombination sites, were subjected to cycle sequence reactions either by BigDye Terminators or by BigDye Primers (DNA Sequencing kit; Applied Biosystems). The sequenced fragments were precipitated and analyzed using an automated sequencer (ABI 310, 377, or 3700).

Southern Blotting.
Genomic DNA was digested with BamH1 or EcoR1, and run on agarose gels (0.8%) for 16 h in Tris-borate EDTA buffer. DNA was denatured and transferred to nylon membranes (Hybond N+; Amersham). Two different probes were generated using RT-PCR, and primers in exons 16 and 20 or 16 and 24. Purified fragments were radioactive labeled using the Random labeling kit (Roche). The hybridizations were carried out overnight at 65°C in Quick-hyb (Stratagene). After washing, the filters were exposed to a phosphorimager screen (Fuji) for quantification or to Kodak X-Omat film.

	Results and Discussion

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
For each of the 24 exons of BRCA1 we designed probes, including two probes for the large exon 11 to establish the exon-specific quantification. Polymorphic sequences were avoided, because they could hamper hybridization and quantification. Furthermore, the ligation sites of the exon 1a, 1b, and 2 probes were located at sequences differing from the pseudo-BRCA1 exons (12) . Probes located more upstream of the BRCA1 gene were not included in the test, because the rearrangements reported thus far always included one or more exons of BRCA1 gene. An additional seven control probes served as quantification reference, allowing the accurate detection of a copy number change of BRCA1 exons or the entire gene.

To automate the interpretation of the fragment analysis we normalized the relative quantity of each of the amplified probes in each sample, using the relative copy number of two for the control probes. The MLPA analysis of 90 control samples yielded highly reproducible results, both for BRCA1 and non-BRCA1 probes (Fig. 2 , top panels). The limited variation allows an accurate discrimination between carriers of deletions and duplications or noncarriers.

View larger version (42K): [in this window] [in a new window]   Fig. 2. Quantitative MLPA analysis of controls and BRCA1 mutation carriers. The quantitative results are represented as box plots with median relative copy numbers; 50% of the samples are within the box, 95% within the error bars. The first and second panels show the quantitative analysis of the peak areas for the BRCA1 and non-BRCA1 probes in 90 control samples. The SD is 3–11% depending on the exon. The bottom panels show the quantitative analysis of known BRCA1 mutation carriers, which were used to validate the method. Data were obtained from independent experiments (n = 6) and show SDs from 3 to 6%, depending on exon and sample; bars, ±SD.

Among 805 families tested between 1995 and 2001 in our two diagnostic laboratories (Netherlands Cancer Institute and VU University Medical Center) a mutation with a predicted pathogenic effect was identified in 144 families, using denaturing gradient gel electrophoresis, denaturing high performance liquid chromatography, protein truncation test, or mutation-specific tests. A BRCA1 mutation was detected in 116 families, 28 families of which with a deletion of exon 13 or 22. A BRCA2 mutation was found in 28 families. Using MLPA, we have screened the remaining 661 families (843 individuals) and detected 5 families with aberrant exon copy numbers (Fig. 3) . Two novel deletions were identified: a deletion of exon 8 in case 596 and a deletion of the exons 20–22 in case 210. In addition, two duplications were found: a duplication of exon 13 (case 465) and a novel duplication of exons 21–23 (case 121). Finally, in case 1673 MLPA suggests a relative copy number of four for exons 17–19, being the first example of exon triplication in the BRCA1 gene. Repeated experiments showed similar results as can be seen in the box-plot representations.

View larger version (37K): [in this window] [in a new window]   Fig. 3. MLPA identifies 5 different mutations in 5 families. Out of 661 families analyzed by MLPA, 5 families were shown to harbor aberrant gene copy numbers of one or more BRCA1 exons. In the box plot-panels only part of the complete BRCA1 quantitative MLPA analysis is shown. Results were obtained from three to six independent experiments; bars, ±SD.

PCR and/or Southern blotting were carried out to verify the gene rearrangements detected by MLPA. PCR analysis showed that the duplication of exon 13 in case 465 was identical to the duplication described by Puget et al. (Ref. 5 ; data not shown). For the novel deletions, we used various combinations of PCR primers to obtain a junction fragment for sequence analysis. We found that the exon 8 deletion in case 596 starts at position IVS7–1129 and comprises 1458 bp including exon 8. The deletion of exons 20, 21, and 22 starts at position IVS19–2840 and comprises 11,395 nt. Southern blotting was used to investigate the amplifications of exons 21–23 and 17–19 (Fig. 4a) . The BamH1 digestion of case 121 resulted in an extra fragment of 7.5 kb. Additional analysis by PCR and sequencing showed that the duplication of exons 21–23 consisted of a tandem duplicated fragment of 7654 nt starting at position IVS23 + 343 (Fig. 4b) . In case 1673, the EcoR1 digestion generated an extra band of 8 kb (Fig. 4a) . Quantitative analysis of this band confirmed the presence of two additional copies of the exons 17–19. Combined with the fact that case 1673 is heterozygous for several BRCA1 polymorphisms, we conclude that one allele contains three copies of exons 17–19 in tandem repeat. Sequence analysis showed that the triplication of exons 17–19 starts at IVS19 + 1681 and comprises an amplicon of 8352 nt (Fig. 4b) . Because >40% of the BRCA1 genomic sequence consists of Alu repeats it is not surprising that all five of the genomic breakpoints are located in Alu elements and, thus, are likely caused by Alu recombination (14) .

View larger version (45K): [in this window] [in a new window]   Fig. 4. Southern blot and PCR confirm the novel amplifications in BRCA1. a, genomic DNA from case 121, suspected carrier of an amplification of exons 21–23, and two controls were digested using BamH1 and, after blotting, hybridized using a RT-PCR probe containing exons 16–24. The autoradiogram shows a novel fragment of 7 kb only present in case 121. DNA from case 1673, identified by MLPA as carrier of two additional copies of exons 17–19, was digested using EcoR1 and, after blotting, hybridized with a RT-PCR probe encompassing exons 16–20. An additional band of 8 kb is observed in the mutant sample only. This band is of similar intensity as the wild-type EcoR1 band of 9.5 kb containing exons 17–19. b, the genomic organization of the amplifications was subsequently assessed by PCR and sequence analysis using different primer combinations. The size of the amplified sequences as determined by sequencing is comparable with the size of the extra bands observed after Southern blot analysis, which indicates that the amplified sequences are amplified in tandem.

Our results show that MLPA is a rapid, reliable, and sensitive technique, which allows high-throughput screening. This is of importance, as many diagnostic laboratories have collected in the recent years hundreds or even thousands of individuals/families with a predisposition to breast/ovarian cancer. With the BRCA1-MLPA test, it is feasible to analyze all of these individuals and families for the presence of large genomic deletions and duplications. And, therefore, we consider the BRCA1-MLPA test a major improvement on the current diagnostic testing for hereditary breast and/or ovarian cancer.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at Department of Clinical and Human Genetics, VU Medical Center, van der Boechorststraat 7, 1081 BT, Amsterdam, the Netherlands. Phone: 31-20-4448278; Fax: 31-20-4448293; E-mail: g.pals{at}VUmc.nl

² Internet address: http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/.

³ The abbreviations used are: MLPA, multiplex ligation-dependent probe amplification; nt, nucleotide; RT-PCR, reverse transcription-PCR.

⁴ Internet address: http://www.mrc-holland.com.

Received 11/11/02. Accepted 2/18/03.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 

1. Puget N., Stoppa-Lyonnet D., Sinilnikova O. M., Pages S., Lynch H. T., Lenoir G. M., Mazoyer S. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res., 59: 455-461, 1999.[Abstract/Free Full Text]
2. Casilli F., Di Rocco Z. C., Gad S., Tournier I., Stoppa-Lyonnet D., Frebourg T., Tosi M. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum. Mutat., 20: 218-226, 2002.[Medline]
3. Unger, M. A., Nathanson, K. L., Calzone, K., Antin-Ozerkis, D., Shih, H. A., Martin, A. M., Lenoir, G. M., Mazoyer, S., and L. W. B. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am. J. Hum. Genet. 67: 841–850, 2000.
4. Petrij-Bosch A., Peelen T., van Vliet M., van Eijk R., Olmer R., Drusedau M., Hogervorst F. B., Hageman S., Arts P. J., Ligtenberg M. J., Meijers-Heijboer H., Klijn J. G., Vasen H. F., Cornelisse C. J., van’t Veer L. J., Bakker E., van Ommen G. J., Devilee P. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat. Genet., 17: 341-345, 1997.[Medline]
5. Puget N., Sinilnikova O. M., Stoppa-Lyonnet D., Audoynaud C., Pages S., Lynch H. T., Goldgar D., Lenoir G. M., Mazoyer S. An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation?. Am. J. Hum. Genet., 64: 300-302, 1999.[Medline]
6. Swensen J., Hoffman M., Skolnick M. H., Neuhausen S. L. Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family. Hum. Mol. Genet., 6: 1513-1517, 1997.[Abstract/Free Full Text]
7. Rohlfs E. M., Puget N., Graham M. L., Weber B. L., Garber J. E., Skrzynia C., Halperin J. L., Lenoir G. M., Silverman L. M., Mazoyer S. An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer, 28: 300-307, 2000.[Medline]
8. Montagna M., Santacatterina M., Torri A., Menin C., Zullato D., Chieco-Bianchi L., D’Andrea. E. Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families. Oncogene, 18: 4160-4165, 1999.[Medline]
9. Schouten J. P., McElgunn C. J., Waaijer R., Zwijnenburg D., Diepvens F., Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res., 30: 1-13, e57 2002.
10. Gille J. J., Hogervorst F. B., Pals G., Wijnen J., van Schooten R. J., Dommering C. J., Meijer G. A., Craanen M. E., Nederlof P. M., de Jong D., McElgunn C. J., Schouten J. P., Menko F. H. Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br. J. Cancer, 87: 892-897, 2002.[Medline]
11. Shattuck-Eidens D., McClure M., Simard J., Labrie F., Narod S., Couch F., Hoskins K., Weber B., Castilla L., Erdos M., et al A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA, 273: 535-541, 1995.[Abstract]
12. Brown M. A., Xu C. F., Nicolai H., Griffiths B., Chambers J. A., Black D., Solomon E. The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21. Oncogene, 12: 2507-2513, 1996.[Medline]
13. Ligtenberg M. J., Hogervorst F. B., Willems H. W., Arts P. J., Brink G., Hageman S., Bosgoed E. A., Van der Looij E., Rookus M. A., Devilee P., Vos E. M., Wigbout G., Struycken P. M., Menko F. H., Rutgers E. J., Hoefsloot E. H., Mariman E. C., Brunner H. G., van’t Veer L. J. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br. J. Cancer, 79: 1475-1478, 1999.[Medline]
14. Smith T. M., Lee M. K., Szabo C. I., Jerome N., McEuen M., Taylor M., Hood L., King M. C. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res., 6: 1029-1049, 1996.[Abstract/Free Full Text]

This article has been cited by other articles:

				C Bonnet, S Krieger, M Vezain, A Rousselin, I Tournier, A Martins, P Berthet, A Chevrier, C Dugast, V Layet, et al. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene J. Med. Genet., July 1, 2008; 45(7): 438 - 446. [Abstract] [Full Text] [PDF]

				D. E. Freedberg, S. H. Rigas, J. Russak, W. Gai, M. Kaplow, I. Osman, F. Turner, J. A. Randerson-Moor, A. Houghton, K. Busam, et al. Frequent p16-Independent Inactivation of p14ARF in Human Melanoma J Natl Cancer Inst, June 4, 2008; 100(11): 784 - 795. [Abstract] [Full Text] [PDF]

				J. R. Pedersen-White, L. P. Chorich, D. P. Bick, R. J. Sherins, and L. C. Layman The prevalence of intragenic deletions in patients with idiopathic hypogonadotropic hypogonadism and Kallmann syndrome Mol. Hum. Reprod., June 1, 2008; 14(6): 367 - 370. [Abstract] [Full Text] [PDF]

				W. Yuan, W. Wang, B. Cui, T. Su, Y. Ge, L. Jiang, W. Zhou, and G. Ning Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry Endocr. Relat. Cancer, March 1, 2008; 15(1): 343 - 350. [Abstract] [Full Text] [PDF]

				I. L. Bergval, R. N. C. P. Vijzelaar, E. R. Dalla Costa, A. R. J. Schuitema, L. Oskam, A. L. Kritski, P. R. Klatser, and R. M. Anthony Development of Multiplex Assay for Rapid Characterization of Mycobacterium tuberculosis J. Clin. Microbiol., February 1, 2008; 46(2): 689 - 699. [Abstract] [Full Text] [PDF]

				R H Scott, J Douglas, L Baskcomb, A O Nygren, J M Birch, T R Cole, V Cormier-Daire, D M Eastwood, S Garcia-Minaur, P Lupunzina, et al. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation J. Med. Genet., February 1, 2008; 45(2): 106 - 113. [Abstract] [Full Text] [PDF]

				E. M. John, A. Miron, G. Gong, A. I. Phipps, A. Felberg, F. P. Li, D. W. West, and A. S. Whittemore Prevalence of Pathogenic BRCA1 Mutation Carriers in 5 US Racial/Ethnic Groups JAMA, December 26, 2007; 298(24): 2869 - 2876. [Abstract] [Full Text] [PDF]

				A De Luca, I Bottillo, M C Dasdia, A Morella, V Lanari, L Bernardini, L Divona, S Giustini, L Sinibaldi, A Novelli, et al. Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification J. Med. Genet., December 1, 2007; 44(12): 800 - 808. [Abstract] [Full Text] [PDF]

				P. Ang, I. H.K. Lim, T.-C. Lee, J.-T. Luo, D. C.T. Ong, P. H. Tan, and A. S.G. Lee BRCA1 and BRCA2 Mutations in an Asian Clinic-based Population Detected Using a Comprehensive Strategy Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2276 - 2284. [Abstract] [Full Text] [PDF]

				P. Lonning, S Knappskog, V Staalesen, R Chrisanthar, and J. Lillehaug Breast cancer prognostication and prediction in the postgenomic era Ann. Onc., August 1, 2007; 18(8): 1293 - 1306. [Abstract] [Full Text] [PDF]

				P. M. Machado, R. D. Brandao, B. M. Cavaco, J. Eugenio, S. Bento, M. Nave, P. Rodrigues, A. Fernandes, and F. Vaz Screening for a BRCA2 Rearrangement in High-Risk Breast/Ovarian Cancer Families: Evidence for a Founder Effect and Analysis of the Associated Phenotypes J. Clin. Oncol., May 20, 2007; 25(15): 2027 - 2034. [Abstract] [Full Text] [PDF]

				B. B.J. Hermsen, S. von Mensdorff-Pouilly, J. Berkhof, P. J. van Diest, J. J.P. Gille, F. H. Menko, M. A. Blankenstein, P. Kenemans, and R. H.M. Verheijen Serum CA-125 in Relation to Adnexal Dysplasia and Cancer in Women at Hereditary High Risk of Ovarian Cancer J. Clin. Oncol., April 10, 2007; 25(11): 1383 - 1389. [Abstract] [Full Text] [PDF]

				D. Mei, E. Parrini, M. Pasqualetti, G. Tortorella, E. Franzoni, U. Giussani, C. Marini, S. Migliarini, and R. Guerrini Multiplex ligation-dependent probe amplification detects DCX gene deletions in band heterotopia Neurology, February 6, 2007; 68(6): 446 - 450. [Abstract] [Full Text] [PDF]

				V. M. Howell, J. W. Cardinal, A.-L. Richardson, O. Gimm, B. G. Robinson, and D. J. Marsh Rapid Mutation Screening for HRPT2 and MEN1 Mutations Associated with Familial and Sporadic Primary Hyperparathyroidism J. Mol. Diagn., November 1, 2006; 8(5): 559 - 566. [Abstract] [Full Text] [PDF]

				N. Sadeghifard, V. Gurtler, M. Beer, and R. J. Seviour The Mosaic Nature of Intergenic 16S-23S rRNA Spacer Regions Suggests rRNA Operon Copy Number Variation in Clostridium difficile Strains Appl. Envir. Microbiol., November 1, 2006; 72(11): 7311 - 7323. [Abstract] [Full Text] [PDF]

				F Casilli, I Tournier, O M Sinilnikova, F Coulet, F Soubrier, C Houdayer, A Hardouin, P Berthet, H Sobol, V Bourdon, et al. The contribution of germline rearrangements to the spectrum of BRCA2 mutations. J. Med. Genet., September 1, 2006; 43(9): e49 - e49. [Abstract] [Full Text] [PDF]

				K. E. Malone, J. R. Daling, D. R. Doody, L. Hsu, L. Bernstein, R. J. Coates, P. A. Marchbanks, M. S. Simon, J. A. McDonald, S. A. Norman, et al. Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years Cancer Res., August 15, 2006; 66(16): 8297 - 8308. [Abstract] [Full Text] [PDF]

				M. de la Hoya, S. Gutierrez-Enriquez, E. Velasco, A. Osorio, A. S. de Abajo, A. Vega, R. Salazar, E. Esteban, G. Llort, R. Gonzalez-Sarmiento, et al. Genomic Rearrangements at the BRCA1 Locus in Spanish Families with Breast/Ovarian Cancer Clin. Chem., August 1, 2006; 52(8): 1480 - 1485. [Abstract] [Full Text] [PDF]

				I. Warshawsky, O. B. Chernova, C. A. Hubner, R. Stindl, M. Henneke, A. Gal, and M. R. Natowicz Multiplex Ligation-Dependent Probe Amplification for Rapid Detection of Proteolipid Protein 1 Gene Duplications and Deletions in Affected Males and Carrier Females with Pelizaeus-Merzbacher Disease Clin. Chem., July 1, 2006; 52(7): 1267 - 1275. [Abstract] [Full Text] [PDF]

				N C M Hearle, M F Rudd, W Lim, V Murday, A G Lim, R K Phillips, P W Lee, J O'Donohue, P J Morrison, A Norman, et al. Exonic STK11 deletions are not a rare cause of Peutz-Jeghers syndrome. J. Med. Genet., April 1, 2006; 43(4): e15 - e15. [Abstract] [Full Text] [PDF]

				T. Walsh, S. Casadei, K. H. Coats, E. Swisher, S. M. Stray, J. Higgins, K. C. Roach, J. Mandell, M. K. Lee, S. Ciernikova, et al. Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer JAMA, March 22, 2006; 295(12): 1379 - 1388. [Abstract] [Full Text] [PDF]

				R. A. Oldenburg, K. Kroeze-Jansema, H. Meijers-Heijboer, C. J. van Asperen, N. Hoogerbrugge, I. van Leeuwen, H. F.A. Vasen, A.-M. Cleton-Jansen, J. Kraan, J. J. Houwing-Duistermaat, et al. Characterization of Familial Non-BRCA1/2 Breast Tumors by Loss of Heterozygosity and Immunophenotyping. Clin. Cancer Res., March 15, 2006; 12(6): 1693 - 1700. [Abstract] [Full Text] [PDF]

				C. T. M. Brekelmans, C. Seynaeve, M. Menke-Pluymers, H. T. Bruggenwirth, M. M. A. Tilanus-Linthorst, C. C. M. Bartels, M. Kriege, A. N. van Geel, C. M. G. Crepin, J. C. Blom, et al. Survival and prognostic factors in BRCA1-associated breast cancer Ann. Onc., March 1, 2006; 17(3): 391 - 400. [Abstract] [Full Text] [PDF]

				S Agata, M Dalla Palma, M Callegaro, M C Scaini, C Menin, C Ghiotto, O Nicoletto, G Zavagno, L Chieco-Bianchi, E D'Andrea, et al. Large genomic deletions inactivate the BRCA2 gene in breast cancer families J. Med. Genet., October 1, 2005; 42(10): e64 - e64. [Abstract] [Full Text] [PDF]

				J Douglas, K Tatton-Brown, K Coleman, S Guerrero, J Berg, T R P Cole, D FitzPatrick, Y Gillerot, H E Hughes, D Pilz, et al. Partial NSD1 deletions cause 5% of Sotos syndrome and are readily identifiable by multiplex ligation dependent probe amplification J. Med. Genet., September 1, 2005; 42(9): e56 - e56. [Abstract] [Full Text] [PDF]

				E. T. Renkonen, P. Nieminen, W. M. Abdel-Rahman, A.-L. Moisio, I. Jarvela, S. Arte, H. J. Jarvinen, and P. Peltomaki Adenomatous Polyposis Families That Screen APC Mutation-Negative by Conventional Methods Are Genetically Heterogeneous J. Clin. Oncol., August 20, 2005; 23(24): 5651 - 5659. [Abstract] [Full Text] [PDF]

				A. O. H. Nygren, N. Ameziane, H. M. B. Duarte, R. N. C. P. Vijzelaar, Q. Waisfisz, C. J. Hess, J. P. Schouten, and A. Errami Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences Nucleic Acids Res., August 16, 2005; 33(14): e128 - e128. [Abstract] [Full Text] [PDF]

				A M Woodward, T A Davis, A G S Silva, kConFab Investigators, J A Kirk, and J A Leary Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families J. Med. Genet., May 1, 2005; 42(5): e31 - e31. [Abstract] [Full Text] [PDF]

				E. B. Gomez-Garcia, T. Ambergen, M. J. Blok, and A. van den Wijngaard Patients With an Unclassified Genetic Variant in the BRCA1 or BRCA2 Genes Show Different Clinical Features From Those With a Mutation J. Clin. Oncol., April 1, 2005; 23(10): 2185 - 2190. [Abstract] [Full Text] [PDF]

				A. S. Whittemore, G. Gong, E. M. John, V. McGuire, F. P. Li, K. L. Ostrow, R. DiCioccio, A. Felberg, and D. W. West Prevalence of BRCA1 Mutation Carriers among U.S. Non-Hispanic Whites Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2078 - 2083. [Abstract] [Full Text] [PDF]

				I. Tournier, B. B.-d. Paillerets, H. Sobol, D. Stoppa-Lyonnet, R. Lidereau, M. Barrois, S. Mazoyer, F. Coulet, A. Hardouin, A. Chompret, et al. Significant Contribution of Germline BRCA2 Rearrangements in Male Breast Cancer Families Cancer Res., November 15, 2004; 64(22): 8143 - 8147. [Abstract] [Full Text] [PDF]

				A. Pavlicek, V. N. Noskov, N. Kouprina, J. C. Barrett, J. Jurka, and V. Larionov Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition Hum. Mol. Genet., November 15, 2004; 13(22): 2737 - 2751. [Abstract] [Full Text] [PDF]

				E. Eldering, C. A. Spek, H. L. Aberson, A. Grummels, I. A. Derks, A. F. de Vos, C. J. McElgunn, and J. P. Schouten Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways Nucleic Acids Res., December 1, 2003; 31(23): e153 - e153. [Abstract] [Full Text] [PDF]

				H R Slater, D L Bruno, H Ren, M Pertile, J P Schouten, and K H A Choo Rapid, high throughput prenatal detection of aneuploidy using a novel quantitative method (MLPA) J. Med. Genet., December 1, 2003; 40(12): 907 - 912. [Full Text]

				D G R Evans, M Bulman, K Young, D Gokhale, and F Lalloo Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families J. Med. Genet., September 1, 2003; 40(9): e107 - 107. [Full Text] [PDF]

This Article Abstract Full Text (PDF)